title: Pharmacological action and clinical results of Omarigliptin (MARIZEV®tablet), a novel dipeptidyl peptidase-4 inhibitor for once-weekly treatment of Type 2 diabetes.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Ito
authors.forename: Masahiko
authors.initials: M
authors.lastname: Mori
authors.forename: Yuki
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Taro
authors.initials: T
authors.lastname: Okamoto
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006574:Heterocyclic Compounds, 2-Ring / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D007004:Hypoglycemic Agents; D066298:In Vitro Techniques; D051379:Mice; D011714:Pyrans / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: C587539:2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006574:Heterocyclic Compounds, 2-Ring; D007004:Hypoglycemic Agents; D011714:Pyrans